(Q41703681)

7 October 2017

title

Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream (English)

1 reference

7 October 2017

K R Beutner

1

1 reference

7 October 2017

J K Geisse

2

1 reference

7 October 2017

D Helman

3

1 reference

7 October 2017

T L Fox

4

1 reference

7 October 2017

A Ginkel

5

1 reference

7 October 2017

M L Owens

6

1 reference

7 October 2017

language of work or name

English

0 references

publication date

1 December 1999

1 reference

Journal of the American Academy of Dermatology

7 October 2017

published in

1 reference

7 October 2017

volume

41

1 reference

7 October 2017

issue

6

1 reference

7 October 2017

page(s)

1002-1007

1 reference

Guidelines of care for basal cell carcinoma. The American Academy of Dermatology Committee on Guidelines of Care

7 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970261-6

7 January 2021

Nonmelanoma cancers of the skin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970261-6

7 January 2021

Cytokine induction by the immunomodulators imiquimod and S-27609

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970261-6

7 January 2021

Imiquimod 5% cream (Aldara).

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970261-6

7 January 2021

Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970261-6

7 January 2021

Treatment of genital warts with an immune-response modifier (imiquimod).

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970261-6

7 January 2021

Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970261-6

7 January 2021

Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970261-6

7 January 2021

A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970261-6

7 January 2021

Intralesional interferon therapy for basal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970261-6

7 January 2021

Treatment of basal cell carcinoma with intralesional interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970261-6

7 January 2021

Expression of CD80 (B7/BB-1) and CD28 in human white blood cells treated with urocanic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970261-6

7 January 2021

Sunlight induced progression of AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970261-6

7 January 2021

Skin cancer in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970261-6

7 January 2021

The role of urocanic acid in UV-induced immunosuppression: recent advances (1992-1994).

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970261-6

7 January 2021

Chromophore for UV-induced immunosuppression: urocanic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970261-6

7 January 2021

Trans-urocanic acid, a natural epidermal constituent, inhibits human natural killer cell activity in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970261-6

7 January 2021

Recurrence rate of positive margin basal cell carcinoma: results of a five-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970261-6

7 January 2021

The significance of incomplete excision in patients with basal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2899%2970261-6

7 January 2021

10.1016/S0190-9622(99)70261-6

Identifiers

DOI

1 reference

7 October 2017

1 reference